Table 2 Performance of individual and combined biomarkers in detecting recurrent ovarian cancer
From: VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
| Â | AUC (95% CI) | SN (%) | SP (%) |
|---|---|---|---|
Healthy controls vs primary OvCa | |||
 IL-6 R alpha | 0.618 (0.492–0.743) | 21.7& | 85 |
 GDF-15 | 0.737 (0.624–0.849) | 43.5# | 85 |
 IL-6 | 0.739 (0.626–0.852) | 41.3$ | 85 |
 GDF-15 + IL-6 + IL-6 R alpha | 0.844 (0.758–0.930) | 65.2 | 85 |
Healthy controls vs recurrent OvCa | |||
 IL-6 R alpha | 0.650 (0.519–0.782) | 30.4& | 83 |
 IL-6 | 0.801 (0.685–0.916) | 50.0& | 83 |
 GDF-15 | 0.856 (0.771–0.942) | 69.6# | 83 |
 GDF-15 + IL-6 + IL-6 R alpha | 0.904 (0.829–0.979) | 84.8 | 83 |
Primary vs recurrent OvCa | |||
 CA-125 | 0.700 (0.551–0.848) | 37.5# | 83 |
 VCAM-1 | 0.729 (0.580–0.879) | 58.3 | 83 |
 CA-125 + VCAM-1 | 0.813 (0.687–0.938) | 70.8 | 83 |